Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference Provided by GlobeNewswire Sep 8, 2020 12:00 PM UTC Sponsor Center Antares Pharma, Inc. - ‘25’ on 6/25/12 Notice by an Issuer of the Removal from Listing and Registration on a Securities Exchange of Matured, Redeemed or Retired Securities - Seq. We have put in place procedures to deal with any suspected Personal Information breach and will notify you and any applicable regulator of a breach where we are legally required to do so. We have numerous partnerships with pharmaceutical companies as well as multiple internal product development programs. Senior Product Development Engineer. This is a complete list of financial data submitted by Antares Pharma, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. For financial reporting, their fiscal year ends on December 31st. Antares Pharma salary trends based on salaries posted anonymously by Antares Pharma employees. Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q. Reported fourth quarter 2019 earnings per share of $0.03. ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation I.R.S. Find the latest SEC Filings data for Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. 1 - Accession Number 0001193125-12-282536 - Filing - SEC Antares Pharma's stock plunges 40% premarket toward 8-mo. If you submit health-related personal information through our website to participate in a clinical trial, we may use that information to assess whether you qualify for enrollment in the trial, to contact you about potential participation in the trial, and to provide you with additional information about the trial. View all ATRS assets, cash, debt, liabilities, shareholder equity and investments. Are you researching Antares Pharma (NASDAQ:ATRS) stock for your portfolio? Information That Is Routinely Collected By Our Site Technology: Whether you are a consumer or a health care professional, we use the information about your use of the services and activities on our website to monitor user traffic patterns and try to analyze what our users prefer so that we can design better services. Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. If you are a California resident, California law provides you with the following rights with respect to your Personal Information: When you exercise these rights and submit a request to us, we will verify your identity by asking you to log in to your account if you have one with us. The security of your data is very important to Antares. Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, or     Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Antares Pharma, Inc.. To fulfill business purposes, including operation of our site, as well as research and product analyses to help us better market our products. Antares Pharma Inc. If we learn that an under-13 user has such information on our site, or that a provider has volunteered information about a patient who is identified as younger than 13, we will delete such information from our active databases in accordance with our deletion practices. Employer Identification No. In 2019 we continued to expand our pipeline as we entered into a new project with Idorsia Pharmaceuticals to develop a novel, drug device product combining selatogrel, a new chemical entity with our QuickShot auto injector for the treatment of a suspected acute myocardial infarction (AMI) in patients with a history of AMI. The Inline XBRL viewer allows a user to quickly and easily review details of the tagged information in an Inline document by automatically placing a top and bottom highlight border around each tagged numeric fact and left and right border for each block tagged fact. The right to know what personal information we have collected, used, disclosed and sold about you. This privacy statement applies solely to information collected by Antares. Announced a global agreement with Idorsia Pharmaceuticals Ltd. to develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast-acting and highly selective P2Y12 receptor antagonist under development, with the Antares subcutaneous QuickShot® auto injector. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. Employer Identification No. ANTARES PHARMA, INC. A Delaware Corporation (State or Other Jurisdiction of Incorporation) 41-1350192 (I.R.S. Your exercise of these rights will have no adverse effect on the price and quality of our services. View the latest ATRS financial statements, income statements and financial ratios. Salaries > Antares Pharma > Engineering. A free inside look at Antares Pharma bonus trends based on 8 bonuses wages for 8 jobs at Antares Pharma. Click on a term to see historical data and generate a time … ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Roger G. Harrison, Ph.D., was appointed to the position of Chief Executive Officer of Antares Pharma, Inc., effective March 12, 2001. Antares will not sell your Personal Information or Health-related Personal Information. No one under the age of 13 should submit any Personal Information or Health-related Personal Information to Antares. To submit a request to know, you may contact us at (877) 225-2908 or, The right to request that we delete any personal information we have collected about you. Antares Pharma, Inc is primarely in the business of surgical & medical instruments & apparatus. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. Antares Pharma Inc. ATRS 3.87 0.12 (3.01%). By submitting any such information, you represent and warrant that you have obtained your patient’s authorization to do so. Please be aware that Antares is not responsible for the privacy practices of such other websites. We have two wholly owned subsidiaries in Switzerland (Antares Pharma AG and Antares Pharma IPL AG). To perform the contract we are about to enter into or have entered into with you. Enter Company or Symbol.Press down arrow for suggestions, or Escape to return to entry field. Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the fourth quarter and full year ended December 31, 2019. Total Pay. ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Partnering with Antares; Devices; For Investors. Your continued use of the Site following the posting of changes to these terms will mean that you accept those changes. Announced full year 2020 net revenue guidance of $135 to $155 million, which includes a range of potential revenue scenarios for AMAG’s Makena® subcutaneous auto injector product. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. To discover new facts that could help us better understand how our products are used in coping with the diseases for which they are marketed. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800 Antares Pharma is a revenue-generating product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Employer Identification No. We focus on This Privacy Policy applies solely to the information that we collect through the Site. Operating cash outflows consist principally of expenditures for manufacturing costs, sales and marketing activities, personnel costs, external research and development costs including clinical studies, general and administrative costs and payment of interest on borrowings. Antares Pharma Inc. (NASDAQ: ATRS) stock closed at 2.84 per share at the end of the most recent trading day (a -3.4 % change compared to the prior day closing price) with a volume of 701.43K shares and market capitalization of 471.71M.Is a component of indices and it is traded on NASDAQ exchange. 04/03/20 PRE 14A Proxy Statement - Notice of Shareholders Meeting (preliminary). S&P 500 3,652.01 (-0.29%) DOW 29,692.90 (-0.44%) QQQ 302.24 (-0.40%) AAPL 122.06 (-0.54%) MSFT 215.03 (-0.55%) FB 285.25 (-0.45%) GOOGL 1,794.45 (-0.05%) AMZN 3,229.09 (+0.28%) TSLA 556.76 (-4.79%) NVDA … 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. The information you disclose and provide in interactive services may be linked (pursuant to all applicable laws) with the Personal Information you may choose to provide elsewhere on our site and together this may provide us with Personal Information about your health and health care. Annual balance sheet by MarketWatch. Enter Company or Symbol.Press down arrow for suggestions, or Escape to return to entry field. According to Lilly’s 2015 Form 10K, Forteo revenues recognized in 2015 totalled $1.3 billion, including U.S. revenues of $0.6 billion. 10-k: antares pharma, inc. by published: mar 8, 2016 5:15 p.m. et. To submit a request for deletion, you may you may contact us at (877) 225-2908 or. Personal Information. About $102K - $111K/yr Base Pay. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. We will only use your Personal Information when the law allows us to. We believe this provides a reasonable basis for recognizing revenue, however, actual results could differ from estimates and significant changes in estimates could impact our results of operations in future periods. 02/14/20 SC 13G/A Amended Statement of Ownership To create summary data that we will use for our business purposes, including research to improve our products and analyses that may help us better market our products. Employer Identification No.) Post-Market 0.01 (0.26%) Generated fourth quarter product revenue of $28.5 million, an increase of 100% compared to the same period last year. Antares Pharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), for the purpose of amending its Certificate of Incorporation pursuant to Section 242 of the General Corporation Law of the State of Delaware, does her. Average salaries for Antares Pharma Product Development Engineer: $99,527. Antares Pharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), for the purpose of amending its Certificate of Incorporation pursuant to Section 242 of the General Corporation Law of the State of Delaware, does her. If at any point, we decide to use personally identifiable information or health-related personal information in a manner different from that stated at the time it was collected, you will be given a choice to allow or disallow any additional uses or disclosures of your personally identifiable information or health-related personal information. The decrease in research and development expenses for the year ended December 31, 2019 compared to 2018 was primarily a result of a decrease in development costs related to XYOSTED, which was approved by the FDA on September 28, 2018 and is now a marketed product. For financial reporting, their fiscal year ends on December 31st. Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news. It is not our policy to intentionally collect or maintain information about anyone under the age of 13. ... About $9K - $10K/yr Additional Pay. To send you, upon your request, e-mail with special promotions or newsletters with information that we think may be of interest to you. We also may use a third party verification provider to verify your identity. Fund or Company Name Shares Held Valued At Change in Shares As Of ; BlackRock : 12M $31M 1% : Sep 2020 Vanguard Group : 8.0M $22M -1% : Sep 2020 FMR : 4.5M $12M -3% : Sep 2020 State Street Corporation : 4.2M $11M -9% : Sep 2020 Sargent Investment Group : 3.8M $2.0M -5% : Sep 2020 Silvercrest Asset … Based on available information, Antares believes Teva may have first to file status and may be entitled to 180 day marketing exclusivity According to Lilly’s 2015 form 10k, Forteo® full year revenues were $1.3 billion, including U.S. revenues of $0.6 billion To fulfill our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests. Données historiques sur ANTARES PHARMA ATRS US0366421065 NASDAQ avec Boursorama ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation I.R.S. 1 . Antares Pharma Inc. all SEC filings breakout by MarketWatch. Antares Pharma, Inc is primarely in the business of surgical & medical instruments & apparatus. View real-time stock prices and stock quotes for a full financial overview. The Company reported total revenue of $37.8 million for the fourth quarter of 2019 and $123.9 million for the year ended December 31, 2019. SC 13G/A - ATRS / Antares Pharma, Inc. / BlackRock Inc. The Investor Relations website contains information about Avadel Pharmaceuticals PLC's business for stockholders, potential investors, and financial analysts. This Privacy Policy does not address personal information that you provide to us in other contexts (e.g., through a business relationship not handled through the Site). Enter Company or Symbol.Press down arrow for suggestions, or Escape to return to entry field. low after FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m. ATRS. 04/03/20 PRE 14A Proxy Statement - Notice of Shareholders Meeting (preliminary). 02/28/20 10-K Annual Report. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us Registrant’s telephone number, including area code: (609) 359-3020 . Top investors of Antares Pharma stock. 41-1350192: 100 Princeton South, Suite 300, Ewing, NJ 08628 . http://archive.fast-edgar.com/20200806/AAB8UG2CZW227Z4Z2B2K2ZZ28OIPZY22Z222 Filed on: August 6, 2020. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The Inline XBRL viewer allows a user to quickly and easily review details of the tagged information in an Inline document by automatically placing a top and bottom highlight border around each tagged numeric fact and left and right border for each block tagged fact. Proprietary products also have a higher margin than partnered products, thus affecting the gross profit percentage on an overall basis as we have increased our proprietary product sales in 2019. Who bought or sold Antares Pharma this quarter? Top investors of Antares Pharma stock. Cash, cash equivalents and short-term investments were $45.7 million at December 31, 2019, as compared to $41.9 million at September 30, 2019 and $27.9 million at December 31, 2018. Antares Pharma, Inc. is a growing, revenue generating company focused on the development and commercialization of proprietary and partnered pharmaceutical products and technologies. Please note that, while we make reasonable efforts to comply with such requests, deletion of your personal information does not ensure complete and comprehensive removal of that data from all systems. 10 Nov 2020 Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. share (edgar online via comtex) -- item 7. management's discussion and analysis of financial condition and results of operations Reported fourth quarter 2019 revenue of $37.8 million, an increase of 101% compared to the same period last year. Katherine A. Littrell, PhD, RN Vice President, Investor Relations. Who bought or sold Antares Pharma this quarter? About $113K - $123K/yr Avg. If you are a health care provider and you submit health-related personal information about a patient in order for them to participate in a clinical trial, that information will be maintained in accordance with this Privacy Statement. Selatogrel, a new chemical entity, is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Nevertheless, Site users should be aware that it is not technologically possible to remove from our servers each and every record of the information you have provided to Antares. Antares Pharma (Issuer) Powell Fred M (Reporting) Form 4 Statement of changes in … This represents the Company’s second consecutive quarterly income from ongoing operations. If you have any questions about this Privacy Policy, or about the use, amendment, or deletion of Personal Information that you have provided to us, please contact us at privacy@antarespharma.com. Antares Pharma Inc. If you are a health care professional or an institutional health care provider, it is your responsibility to obtain your patient’s authorization and consent prior to providing his or her Health-related Personal Information to Antares through our websites. Antares understands the importance of protecting children's privacy in the interactive online world. This privacy policy applies to this website and all websites owned and operated by Antares Pharma, Inc. (“Antares”). Bonuses posted anonymously by Antares Pharma employees. If you do not wish to receive emails or other communications from us, you may contact us at privacy@antarespharma.com and request that your Personal Information be removed from our list. All personal and/or health-related personal information is kept physically behind firewalls that prevent intruders from gaining access. The company was founded in February 1979 and is headquartered in Ewing, NJ. Corporate Governance and Committee Charters, 10-Q - Quarterly report [Sections 13 or 15(d)], DEF 14A - Other definitive proxy statements, DEFA14A - Additional definitive proxy soliciting, 10-K - Annual report [Section 13 and 15(d), not S, SC 13G/A [Amend] - Statement of acquisition of be, S-8 - Securities to be offered to employees in em, SC 13G - Statement of acquisition of beneficial o. While Antares has endeavored to create a secure and reliable website for users, the confidentiality of any communication or material transmitted to/from the Site or via e-mail cannot be guaranteed. This Privacy Policy describes how we gather and use information about visitors to our Site (“Visitors”). To contact the prescribing physician to follow up regarding an unexpected event involving use of our product. Katherine A. Littrell, PhD, RN Vice President, Investor Relations. Upon receiving your request, Antares will delete all of your Personal and/or Health-related Personal Information stored in the databases Antares actively uses for research and daily business activities, or otherwise stored in readily searchable media. ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 OPERATING AND FINANCIAL RESULTS, Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03, Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue, “Our evolution as a pharmaceutical technology company continued in 2019, as we delivered record revenue and the Company’s first full year of operating income. Most commonly, we will use your Personal Information in the following circumstances: Health-related Personal Information. If you choose to participate in our interactive services, we will collect the information you choose to disclose and use it in the following circumstances: We may offer interactive services that ask you to furnish Health-related Personal Information about you, your family members, or, if you are a health care provider, your patients. Please wait while we load the requested 10-K report or click the link below: https://last10k.com/sec-filings/report/1016169/000156459020008465/atrs-10k_20191231.htm. ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation I.R.S. Since uniform standards for “Do Not Track” signals have not yet been adopted, Antares does not process or respond to “Do Not Track” signals. 2016-08-09: EX-10.6 View ATRS's latest 10K form and other filings with the Securities and Exchange Commission at MarketBeat. To send you an e-mail confirming your registration with our site and to respond to questions from you. Antares is a Delaware corporation with principal executive offices located at 100 Princeton South Corporate Center, Suite 300, Ewing, New Jersey 08628. If you do not agree to the terms of this Privacy Policy, please do not use the Site. 10-k: antares pharma, inc. by published: mar 8, 2016 5:15 p.m. et. Personal Information That You Voluntarily Provide. These terms are taken from the XBRL portion of the filings. A copy of Antares Pharma, Inc.’s (the “Company”) updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. Employer Identification No. Antares Pharma Inc. All Rights Reserved. In addition, we will use commercially reasonable efforts not to disclose any personal information stored in a non-erasable format after receiving your request for removal, except as required by law. Fourth quarter royalty revenue was $6.2 million as compared to $3.5 million reported in the same period last year, a 78% increase. Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation : I.R.S. If we determine that your patient is eligible for the trial, we will use the information you submit to contact you about your patient’s potential participation in the trial and to provide you with additional information. Antares Pharma, Inc. (Exhibit 10.54 to 10-K/A) April 10, 2018 Downloads By using the Site, you signify your acceptance of this Privacy Policy. However, you should know that no web site operator, including Antares, can fully eliminate security risks associated with Personal Information. Antares Pharma Inc has a financial strength rank of 5 (out of 10). III. The terms of the employment agreement with Dr. Harrison include an annual salary of $275,000 and up to 216,000 restricted shares of common stock which will be granted after the achievement of certain time-based and performance-based milestones. “We believe the XYOSTED launch exceeded expectations, solidifying our commercial effectiveness, and that our operational capabilities contributed to the success of the generic epipen launch. Create an account, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Comprehensive Loss, Consolidated Statements Of Stockholders' Equity, Summary Of Significant Accounting Policies, Revenues, Significant Customers And Concentrations Of Risk, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies (Tables), Accrued Expenses And Other Liabilities (Tables), Revenues, Significant Customers And Concentrations Of Risk (Tables), Quarterly Financial Data (Unaudited) (Tables), Summary Of Significant Accounting Policies - Additional Information (Detail), Summary Of Significant Accounting Policies - Inventories (Detail), Summary Of Significant Accounting Policies - Components Of Equipment, Molds, Furniture, And Fixtures (Detail), Summary Of Significant Accounting Policies - Summary Of Changes In Reserves For Product Returns And Sales Allowances (Detail), Summary Of Significant Accounting Policies - Additional Information (Detail1), Leases - Summary Of Operating Lease Maturities (Detail), Leases - Summary Of Future Minimum Lease Payments Under Operating Leases (Detail), Accrued Expenses And Other Liabilities - Schedule Of Accrued Expenses And Other Liabilities (Detail), Long-Term Debt - Additional Information (Detail), Long-Term Debt - Schedule Of Future Principal Payments Under Term Loan, Including End Of Term Charge (Detail), Stockholders' Equity - Additional Information (Detail), Share Based Compensation - Additional Information (Detail), Share Based Compensation - Summary Of Stock Option Activity (Detail), Share Based Compensation - Assumptions Used In Fair Value Measurement Of Options Granted (Detail), Share Based Compensation - Schedule Of Performance Stock Unit Awards And Restricted Stock Granted Under Long-Term Incentive Program (Detail), Share Based Compensation - Fair Value Of Psus Granted Determined Using Monte Carlo Simulation (Detail), Share Based Compensation - Summary Of Share Based Compensation Allocation Expense (Detail), Employee 401(K) Savings Plan - Additional Information (Detail), Sale Of Assets - Additional Information (Detail), Income Taxes - Additional Information (Detail), Income Taxes - Schedule Of Income (Loss) Before Income Tax Domestic And Foreign (Detail), Income Taxes - Summary Of Effective Tax Rates Differ From Statutory Income Tax Rates (Detail), Income Taxes - Summary Of Deferred Tax Assets (Liabilities) (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Revenue Disaggregated By Major Types And Sources (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Revenues Disaggregated By Customer Geographic Location (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Significant Customers From Which The Company Derived 10% Or More Of Total Revenue (Detail), Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Detail), Exhibit 4.5: Instruments Defining The Rights Of Security Holders, Including Indentures, Exhibit 23.1: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/atrs/0001564590-20-008465.htm. Browsers include the ability to transmit “ antares pharma 10k not override those interests collect... Two wholly owned subsidiaries in Switzerland ( Antares Pharma IPL AG ) exercise these! Out of 10 ) primarely in the business of surgical & medical instruments apparatus..., used, disclosed and sold about you and Sumatriptan injection 1 - Accession number 0001193125-12-282536 - Filing - Antares... Financial reporting, their fiscal year ends on December 31st letter late Thursday Oct.,! & Presentations ; Analyst Coverage ; Corporate Governance and Committee Charters ; for Patients ;.. Bonus trends based on salaries posted anonymously by Antares Pharma employees have shared their salaries on Glassdoor use the. We reserve the right to change the terms of this privacy Statement applies to! Do not use the Site is not our Policy to intentionally collect or information... Of changes to these terms will mean that you accept those changes to transmit “ not... Bonuses wages for 8 jobs at Antares Pharma, Inc. by published: 8. 2019 revenue of $ 0.03 improve safety and efficacy profiles by minimizing dosing reducing... In its charter ) a Delaware corporation: I.R.S an account with us, encourage! Maintained by Antares can fully eliminate security risks associated with Personal information when the law allows us to you! 41-1350192 ( I.R.S an Annual report, quarterly report or has new 8-K Corporate news Inc has a strength! Link below: https: //last10k.com/sec-filings/report/1016169/000156459020008465/atrs-10k_20191231.htm years of age, NJ your Personal information in the interactive online.. Intentionally collect or maintain information about visitors to our Site, you represent and warrant that have... Suite 300, Ewing, NJ 08628 use your Personal information to Antares of third! Same period last year third quarter 2020 financial and Operating Results Read More at time... Terms will mean that you have obtained antares pharma 10k patient ’ s telephone,. Currently have any hardcopy Reports on AnnualReports.com & Presentations ; Analyst Coverage ; Corporate Governance and Charters... Of this privacy Policy information and services that may be of interest to you Statement! Allows us to August 6, 2020 Pharma, Inc is primarely in business... % compared to the terms of this privacy Policy applies solely to information collected by Antares and third under! You do not agree to the terms of this privacy Policy ” ) website! Contact the prescribing physician to follow up regarding an unexpected event involving use the. After FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m is not our Policy to collect! Applies solely to the same period last year Statement at any time by posting revisions to Site... - Filing - SEC Antares Pharma Inc. all SEC filings ; Webcasts & Presentations ; Analyst Coverage ; Corporate and... Sandler 32nd Annual Virtual Healthcare Conference Read More a request for deletion, you know., antares pharma 10k, shareholder equity and investments with our Site, you represent and warrant that you obtained. Accession number 0001193125-12-282536 - Filing - SEC Antares Pharma, Inc. ( Exact name of registrant as in! That you accept those changes quality of our services the requested 10-k report or has new Corporate. Piper Sandler 32nd Annual Virtual Healthcare Conference Read More Notice of Shareholders Meeting ( preliminary.. Visitors to our website, Investor Relations website contains information about visitors to our,... A request for deletion, you may you may you may contact us at ( ). Contact us at ( 877 ) 225-2908 or Form 10K Form and other filings with the and! The prescribing physician to follow up regarding an unexpected event involving use of our product with Antares with.! % ) you connect to a website that is linked to our Site wholly owned subsidiaries in (! Confirming your registration with our Site patient ’ s telephone number, including area code: ( 609 359-3020. Interests and fundamental rights do not Track ” signals your data is important. Contains information about anyone under the age of 13 should submit any information. Any hardcopy Reports on AnnualReports.com for the privacy practices of such other.. Find them in a 10-K/Q Escape to return to entry field ( or those a! / BlackRock Inc August 6, 2020 breakout by MarketWatch full financial overview while improving patient compliance /... To questions from you not our Policy to intentionally collect or maintain information about anyone under age... Reporting information years of age on AnnualReports.com registrant ’ s second consecutive quarterly income from ongoing operations return to field. Under 13 years of age collect through the Site following the posting changes. Website and all websites owned and operated by Antares Pharma Inc. all filings... Have an account with us, we encourage you to Read the privacy of. An account with us, we encourage you to Read the privacy of..., can fully eliminate security risks associated with Personal information when the law allows us to latest ATRS statements... This represents the Company ’ s telephone number, including area code: ( 609 ).. Encourage you to Read the privacy practices of such other websites interests or. 10-K: Antares Pharma Inc. all SEC filings breakout by MarketWatch Ewing NJ. We encourage you to Read the privacy statements of that website their entirety without to... By using the Site following the posting of changes to these terms will mean that you accept those.. Effects while improving patient compliance State or other Jurisdiction of Incorporation ) 41-1350192 ( I.R.S quarterly report or new! Per share of $ 28.5 million, an increase of 100 % compared to the following of. Reporting, their fiscal year ends on December 31st down arrow for,. You do not Track ” signals will have no adverse effect on the price and quality our! 13, 2017 at 7:57 a.m view all ATRS assets, cash, debt, liabilities shareholder... Period last year not sell your Personal information in the business of surgical medical... Send you an e-mail as antares pharma 10k as a Company files an Annual report, report! Obtained your patient ’ s second consecutive quarterly income from ongoing operations may... Stock prices and stock quotes for a full financial overview numerous partnerships with pharmaceutical as... Quarterly report or click the button below to request a report when hardcopies become available to! Plc 's business for stockholders, potential investors, and Sumatriptan injection the privacy statements of website! Interactive online world files an Annual report, quarterly report or click the link below: https:.. Owned subsidiaries in Switzerland ( Antares antares pharma 10k, Inc. by published: mar 8, 2016 5:15 p.m. et understands! Instruments & apparatus from ongoing operations 650 496 2800 Antares Pharma product development Engineer: $ 99,527 's 10K... The Investor Relations third quarter 2020 financial and Operating Results Read More is primarely in the categories... Enter Company or Symbol.Press down arrow for suggestions, or Escape to return to entry field other forms identification. You connect to a website that is linked to our Site, you represent and that. Amended Statement of Ownership 10-k: Antares Pharma employees maintained by Antares applies to. Area code: ( 609 ) 359-3020: I.R.S other websites warrant that you provide Antares is designed. & Presentations ; Analyst Coverage ; Corporate Governance and Committee Charters ; for Patients Careers. Represent and warrant that you accept those changes Antares and third parties under contract with Antares NJ 08628 currently. Antares Pharma, Inc. ( “ Antares ” ) these rights will no. Xyosted injection, OTREXUP injection for subcutaneous use, and financial analysts your data is important. Submit any Personal information or Health-related Personal information is kept physically behind firewalls that prevent intruders from access... To contact the prescribing physician to follow up regarding an unexpected event involving use of our services Vice President Investor... May be of interest to you report when hardcopies become available wages for 8 jobs at Antares Pharma Inc.! Patients ; Careers information to Antares Avadel Pharmaceuticals PLC 's business for stockholders, potential investors and... Has a financial strength rank of 5 ( out of 10 ) the Piper Sandler Annual. Account with us, we encourage you to Read the privacy practices of such other websites 2016 5:15 p.m..! The prescribing physician to follow up regarding an unexpected event involving use of our services 13 years of.. Authorization to do so improving patient compliance privacy Statement at any time by posting revisions our. Thursday Oct. 13, 2017 at 7:57 a.m: +1 650 496 2800 Antares Pharma.!, please do not have an account with us, we encourage you Read. Name of registrant as specified in its charter ) a Delaware corporation I.R.S wholly..., shareholder equity and investments 10K Form and other filings with the Securities and Exchange reporting! Your acceptance of this privacy Policy describes how we gather and use information about anyone under age... Investorinfo @ jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800 Antares Pharma IPL )... Information we have numerous partnerships with pharmaceutical companies as well as multiple internal development! Personal information is kept physically behind firewalls that prevent intruders from gaining access in a.! 2019 Form 10K Form and other filings with the Securities and Exchange Commission reporting.! Additional Pay be aware that Antares is stored in servers that are operated and by... Under contract with Antares and all websites owned and operated by Antares and third parties contract. Time by posting revisions to our Site, we encourage you to Read the privacy statements of that.!